Trial Profile
Safety and effectiveness of Ombitasvir/paritaprevir/ritonavir+dasabuvir in Hepatitis C Virus (HCV) with or without ribavirin infected patients in a real-life cohort from Latin America
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2018
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 05 Apr 2018 New trial record